CEO Doubles Down Despite Technical Damage
Geert Kersten bought $360,000 of CEL SCI at $1.20, his fourth purchase in 12 months. The technicals are ugly with 88% sell signals across all timeframes, but the RSI at 32 suggests oversold territory. This biotech CEO has been right on timing about 60% of the time historically, though the average returns are modest. Healthcare's been finding its footing after months of policy uncertainty, but you're fighting the tape here.
The Filing
| Ticker | CVM |
| Company | CEL SCI CORP |
| Insider | Geert Kersten, Chief Executive Officer |
| Buy amount | $360,000 |
| Filing date | May 18, 2026 |
| Conviction | Interesting · 53/100 |
| Setup type | Contrarian Setup |
Ultimate members received this analysis in real time.